Perspectives

What biotech startups have to know about Freedom to Operate (FTO) As your biotech startup moves from science to commercialization, at some point an investor,…

What biotech founders need to know about investment agreements You’ve incorporated your company, secured your IP and hit a scientific milestone. Now you need capital!…

Unique insights into AbbVie’s partnering opportunitiesAbbVie is continuously seeking partnering opportunities across therapeutics and aesthetics. As one of the most active players in global pharma,…

How biotech startups can protect their IP in licensing and industry collaborations Your science is solid, your patent is filed and the university is supportive.…

The key financial decisions and priorities for biotech startups At our latest webinar, Hoffmann & Partner walked founders through what financial infrastructure you actually need…

Bringing a therapeutic innovation to market requires more than great science—it also demands long-term strategic thinking about funding, ownership, IP, future partnerships, and potential exit…

How Novo Nordisk partners with academia, biotech companies and beyond Novo Nordisk began with a one-dollar insulin license. Today, it’s a global giant fighting more…

Navigating US & EU Patent Law for Startups – avoiding the common pitfalls If you want to protect your intellectual property with a patent, you…

Filing intellectual property (IP) on novel targets and epitopes Building a strong IP portfolio is complex, especially when securing patents for novel targets and epitopes.…

What’s the ideal deal structure to secure funding for biotech startups? As the biotech funding environment evolves, particularly in early seed and Series A rounds,…